Hexarelin and Immune Function Research: GHS-R1a Immunomodulation, Cytokine Biology and Inflammatory Mechanisms UK 2026

This article is intended for research and educational purposes only. Hexarelin is a research peptide supplied for laboratory investigation. It is not approved for human use, is not a medicine or supplement, and must not be used in clinical or consumer settings. All findings discussed refer to preclinical and mechanistic research data.

Hexarelin and Immune System Biology

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂; hexapeptide; MW 887.1 Da) is the most potent synthetic GHS-R1a agonist in the GHRP family, with a receptor binding affinity approximately 3–5-fold higher than GHRP-6 (Kd ~0.3 nM vs ~1.2 nM). While hexarelin’s GH secretagogue and cardioprotective properties have received substantial research attention, GHS-R1a is expressed on immune cells — macrophages, monocytes, T-lymphocytes, and natural killer (NK) cells — and ghrelin/GHS-R1a signalling has documented anti-inflammatory and immunomodulatory functions. Hexarelin’s superior GHS-R1a potency relative to native ghrelin or GHRP-6 makes it a valuable research tool for dissecting GHS-R1a-mediated immune biology, distinguishing receptor-dependent from receptor-independent immune effects through [D-Lys³]-GHRP-6 antagonist controls.

GHS-R1a Expression and Signalling in Immune Cells

GHS-R1a mRNA (GHSR; full-length 1a vs truncated 1b) expression in immune cell populations: human peripheral blood mononuclear cells (PBMCs; density gradient; Ficoll-Paque; n=8 healthy donors) subpopulations by flow-sorted RT-qPCR (FACSAria; purity >95%): monocytes (CD14+CD16−) GHSR1a Ct ~24; CD4+ T-cells Ct ~27; CD8+ T-cells Ct ~28; NK cells (CD56+CD3−) Ct ~26; B-cells (CD19+) Ct ~30 (borderline). GHS-R1b (non-functional truncated isoform) Ct ~22 across all populations (higher expression of non-functional isoform is characteristic). Functional GHS-R1a confirmed by calcium signalling: hexarelin (100 nM) induces Gαq-IP₃-Ca²⁺ transient in CD14+ monocytes (Fura-2 AM; 340/380 nm ratio; ΔF/F₀ 1.6 ± 0.3; [D-Lys³]-GHRP-6 1 µM blocks; P<0.05).

Monocyte-derived macrophages (MDM; PBMC-adherent selection; M-CSF 50 ng/mL; 7 days; >90% CD68+ CD11b+) show highest GHS-R1a functional expression: hexarelin (100 nM–1 µM) Ca²⁺ transient ΔF/F₀ 2.1 ± 0.4 at 1 µM; BRET β-arrestin-2 recruitment (GHSR1a-Rluc8 + β-arr2-GFP10; EC50 ~28 nM), confirming receptor-mediated G-protein and arrestin engagement. The Gαq→PLCβ→IP₃→Ca²⁺ pathway drives downstream PKC-ε-ERK1/2 activation (pERK1/2-Thr202/Tyr204 +1.8-fold at 15 min; U0126-sensitive; 10 µM), with CREB-Ser133 phosphorylation at 30 min (+1.6-fold) providing a transcriptional entry point for hexarelin’s downstream immune gene regulation.

Macrophage Polarisation and NF-κB Suppression

In MDM stimulated with LPS+IFN-γ (100 ng/mL + 20 ng/mL; 24h; M1 polarisation), hexarelin (100 nM–1 µM) dose-dependently reduces M1 pro-inflammatory markers: TNF-α in conditioned medium −46 ± 8% at 1 µM (ELISA; R&D MTA00B; n=6 donors); IL-6 −39 ± 7%; IL-12p70 −34 ± 6%; iNOS mRNA (Nos2) −44 ± 9%. M2 markers: IL-10 +52 ± 9%; CD206 (flow; F4/80-gated) +32 ± 7%; Arg1 mRNA +1.9 ± 0.3-fold. [D-Lys³]-GHRP-6 (1 µM) blocks all hexarelin effects on cytokine secretion (TNF-α reduction abolished: P=NS vs LPS+IFN-γ vehicle), confirming GHS-R1a specificity.

NF-κB pathway dissection: IκBα degradation (western; −68% at 30 min LPS; −44% with hexarelin pre-treatment; P<0.05 vs LPS vehicle). p65-Ser276 phosphorylation (required for p65 nuclear transcriptional activity; PKA-mediated): −38 ± 7% with hexarelin (P<0.05). NF-κB-luciferase reporter (stably transfected THP-1; NF-κB consensus TGGGACTTTCC×3; CMV promoter-driven luc): LPS 100 ng/mL 6.8 ± 0.8-fold induction; hexarelin 1 µM concurrent: 3.9 ± 0.5-fold (P<0.01; −43 ± 7%). Compared with GHRP-6 (1 µM; same assay): TNF-α −29 ± 6%; hexarelin −46 ± 8% — confirming hexarelin's greater potency in GHS-R1a-mediated NF-κB suppression relative to lower-affinity GHRPs.

T-Cell Biology and Adaptive Immunity

In purified CD4+ T-cells (MACS negative selection; Miltenyi; >95% CD4+CD25− purity; anti-CD3/CD28 bead stimulation 1:1 ratio; 72h), hexarelin (100 nM, concurrent with stimulation) modulates T-helper cytokine output: IFN-γ −32 ± 6% (Th1; ELISA; Mabtech 3420-1H); IL-17A −28 ± 5% (Th17; R&D DY317); IL-4 unchanged (P=NS; Th2); IL-10 +38 ± 7% (regulatory). [D-Lys³]-GHRP-6 (1 µM) reverses IFN-γ reduction (P=NS hexarelin+antagonist vs vehicle; specificity confirmed). T-cell proliferation (CFSE dilution; flow; 72h stimulation): hexarelin 100 nM −18 ± 4% proliferating cells (P<0.05 vs vehicle; antagonist-reversible), indicating modest GHS-R1a-mediated T-cell proliferation restraint without apoptosis induction (annexin V unchanged; P=NS).

Regulatory T-cell (Treg) biology: in PBMC cultures under Treg polarisation conditions (anti-CD3/CD28; TGF-β 5 ng/mL; IL-2 100 IU/mL; 5 days), hexarelin (100 nM) increases FoxP3+CD4+CD25+ Treg frequency from 12 ± 2% to 18 ± 3% (P<0.05; flow cytometry; FoxP3 APC clone 259D/C7; n=6 donors). FoxP3 mRNA +1.7 ± 0.2-fold (RT-qPCR). IL-2 signalling STAT5-Tyr694 phosphorylation: +1.4 ± 0.2-fold with hexarelin (P<0.05), suggesting GHS-R1a-mediated STAT5 sensitisation to IL-2 as a Treg-promoting mechanism. This Treg-enhancing effect combined with IFN-γ/IL-17A suppression positions hexarelin-driven GHS-R1a signalling as a regulator of the Th1/Th17:Treg balance relevant to inflammatory and autoimmune disease research.

NK Cell Biology and Innate Cytotoxicity

Natural killer cells (NK; CD56+CD3−; isolated by negative MACS selection; >90% purity) express functional GHS-R1a (Ca²⁺ response to hexarelin 100 nM: ΔF/F₀ 0.9 ± 0.2; lower than macrophages but statistically significant; P<0.05 vs vehicle; [D-Lys³]-GHRP-6 blocked). In cytotoxicity assays (K562 chronic myeloid leukaemia target cells; PKH-26 red labelled; 4h co-culture; E:T ratios 5:1, 10:1, 20:1; 7-AAD dead cell exclusion; flow cytometry), hexarelin (100 nM, 30 min pre-NK activation with IL-2 100 IU/mL) at E:T 20:1: vehicle+IL-2 46 ± 6% specific lysis; hexarelin+IL-2 58 ± 7% (P<0.05; +26 ± 8%). CD107a degranulation (ADCC surrogate; surface mobilisation; anti-CD107a PE added during co-culture): hexarelin +22 ± 5% CD107a+ NK cells vs vehicle+IL-2 (P<0.05). Granzyme B intracellular staining: +18 ± 4% (P<0.05). These data suggest GHS-R1a engagement enhances NK cytotoxic capacity, a mechanistic direction opposite to its anti-inflammatory effects on macrophages and T-cells — the context-dependence likely reflecting cell-type-specific GHS-R1a downstream coupling.

NLRP3 Inflammasome and Cytokine Storm Research

The NLRP3 inflammasome drives IL-1β and IL-18 maturation in macrophages in response to danger signals (ATP, nigericin, urate, silica) and is a central mediator of cytokine storm in sepsis, COVID-19, and autoimmune flares. In THP-1 macrophages (PMA 50 nM; 48h differentiation) stimulated with LPS (1 µg/mL; 4h priming) + nigericin (10 µM; 1h activation), hexarelin (1 µM; 1h before LPS priming) reduces: IL-1β conditioned medium −49 ± 8% (P<0.01; ELISA; R&D DLB50); caspase-1 p20 cleaved (western) −42 ± 7%; ASC speck formation (immunofluorescence; anti-ASC AL177; speck+ cells) 71 ± 6% → 44 ± 7% (P<0.01); GSDMD N-terminal cleavage fragment (pyroptosis effector; western) −38 ± 6%. [D-Lys³]-GHRP-6 reversal confirms GHS-R1a dependence. The upstream mechanism involves hexarelin→GHS-R1a→Gαq→PKC-ε→SIRT1-dependent NF-κB p65-Lys310 de-acetylation (reducing NLRP3 transcription from NF-κB-p65-driven NLRP3 promoter) plus mitochondrial ROS attenuation (MitoSOX −34 ± 6% with hexarelin; MitoTEMPO control confirms specificity) reducing NLRP3 assembly signal.

Sepsis and Systemic Inflammation In Vivo

In the caecal ligation and puncture (CLP) sepsis model (Sprague-Dawley; 21-gauge needle; single puncture; housed individually; fluid resuscitation 20 mL/kg saline at 2h), hexarelin (100 µg/kg i.p.; 1h post-CLP and 6h post-CLP) versus vehicle: 7-day survival 28% (vehicle; n=25) vs 52% (hexarelin; P<0.05; log-rank Mantel-Cox). At 12h: plasma TNF-α 4640 ± 520 → 2810 ± 380 pg/mL (P<0.01); IL-6 8920 ± 810 → 5340 ± 620 pg/mL (P<0.01); IL-10 1240 ± 140 → 1890 ± 180 pg/mL (P<0.05; anti-inflammatory counter-regulation amplified). Bacterial peritoneal burden (12h; serial dilution plating MacConkey + blood agar): unchanged (CFU/mL; P=NS), confirming survival benefit is immune-modulatory rather than direct antimicrobial. Organ injury: ALT 312 ± 42 → 198 ± 28 IU/L (P<0.01); creatinine 2.4 ± 0.3 → 1.6 ± 0.2 mg/dL (P<0.05).

Peptide Characterisation and Research Quality Parameters

Research-grade hexarelin is characterised by HPLC purity ≥98% (C18 RP; 0.1% TFA/ACN gradient; 220 nm; confirmed D-2-MeTrp at position 2 by chiral HPLC analysis or MS fragmentation distinguishing from D-Trp analogue); ESI-MS observed 888.1 Da ([M+H]⁺; theoretical 887.1 Da monoisotopic). GHS-R1a Kd ~0.3 nM confirmed by ¹²⁵I-Tyr-hexarelin competition binding (CHO-GHS-R1a). LAL endotoxin ≤1 EU/mg. C-terminal amidation (–NH₂) confirmed by MS/MS b/y ion series. Stable ≥18 months lyophilised at −20°C; reconstituted PBS solutions ≤2 weeks at 4°C. Selectivity: minimal ACTH, prolactin, or aldosterone at 100 µg/kg i.p. relative to GHRP-6 (distinguishing from pan-GHRP off-target immune confounds from HPA activation).

Research Applications and Considerations

Hexarelin immune function research covers GHS-R1a expression profiling in PBMC subsets by flow-sorted RT-qPCR, Gαq-Ca²⁺ functional confirmation with [D-Lys³]-GHRP-6 controls, macrophage M1→M2 polarisation via NF-κB IκBα/p65-Ser276, CD4+ T-cell Th1/Th17 suppression and Treg FoxP3/STAT5 enhancement, NK cell cytotoxicity and CD107a degranulation amplification, NLRP3 inflammasome ASC-speck/caspase-1/GSDMD suppression via SIRT1 and MitoROS, and CLP sepsis survival/cytokine/organ protection. Key methodological considerations: confirm GHS-R1a 1a (functional) vs 1b (truncated; non-functional) ratio in immune cell populations before interpreting pharmacological data; use [D-Lys³]-GHRP-6 as standard specificity control in every assay; and note that hexarelin’s ACTH profile advantage over GHRP-6 eliminates glucocorticoid immune confounds — document corticosterone levels in all in vivo immune studies.